Medgenics Announces Global Head, Research and Development, Gary Neil, M.D. Receives FDA Commissioner’s Special Citation Award

WAYNE, Pa. and MISGAV, Israel, June 18, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration’s (FDA) Commissioner’s Special Citation. The Citation was established as an expression of the Commissioner’s personal appreciation, recognizing outstanding and significant service in the public interest related to activities of the FDA. Dr. Neil has been extensively involved with many aspects of FDA policy work, including his work with the Reagan-Udall Foundation for the FDA. The Foundation fosters collaborations between patient groups, industry, academia, and FDA scientists to design and conduct regulatory science research.

This entry was posted in Recent Development News: Q2 - 2014. Bookmark the permalink.